# Vunakizumab in Adults with Spondyloarthritis

> **NCT06770088** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 880 (estimated)

## Conditions studied

- Spondyloarthritis (SpA)

## Interventions

- **DRUG:** vnacicizumab

## Key facts

- **NCT ID:** NCT06770088
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-10
- **Primary completion:** 2026-01-10
- **Final completion:** 2027-12-31
- **Target enrollment:** 880 (ESTIMATED)
- **Last updated:** 2025-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06770088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06770088, "Vunakizumab in Adults with Spondyloarthritis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06770088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*